Amylyx Pharmaceuticals, Inc. (AMLX) Income Statement Analysis

See more : Northern Shield Resources Inc. (NRN.V) Income Statement Analysis – Financial Results

Complete financial analysis of Amylyx Pharmaceuticals, Inc. (AMLX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Amylyx Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Industrial Securities Co.,Ltd. (601377.SS) Income Statement Analysis – Financial Results
National Silicon Industry Group Co., Ltd. (688126.SS) Income Statement Analysis – Financial Results
Luye Pharma Group Ltd. (LYPHF) Income Statement Analysis – Financial Results
Canfor Pulp Products Inc. (CFX.TO) Income Statement Analysis – Financial Results
Trent Limited (TRENT.BO) Income Statement Analysis – Financial Results

Amylyx Pharmaceuticals, Inc. (AMLX)

Industry: Biotechnology

Sector: Healthcare

Website: https://amylyx.com

About Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Metric	2023	2022	2021	2020	2019
Revenue	380.79M	22.23M	285.00K	650.00K	1.43M
Cost of Revenue	25.44M	2.99M	52.00K	24.59M	11.90M
Gross Profit	355.35M	19.24M	233.00K	-23.94M	-10.47M
Gross Profit Ratio	93.32%	86.54%	81.75%	-3,683.69%	-734.43%
Research & Development	128.19M	93.45M	44.04M	24.59M	11.90M
General & Administrative	178.86M	127.13M	38.93M	15.06M	3.08M
Selling & Marketing	9.50M	4.40M	0.00	0.00	0.00
SG&A	188.36M	127.13M	38.93M	15.06M	3.08M
Other Expenses	0.00	3.74M	-285.00K	-650.00K	-1.43M
Operating Expenses	316.54M	220.58M	82.69M	39.01M	13.55M
Cost & Expenses	341.98M	223.57M	82.69M	39.01M	13.55M
Interest Income	16.16M	4.29M	36.00K	14.00K	176.00K
Interest Expense	0.00	4.29M	0.00	2.29M	1.28M
Depreciation & Amortization	1.09M	487.00K	52.00K	1.00K	13.55M
EBITDA	39.89M	-200.85M	-82.64M	-39.00M	1.11M
EBITDA Ratio	10.48%	-905.72%	-29,013.33%	-5,957.08%	-938.22%
Operating Income	38.80M	-201.34M	-82.69M	-39.01M	-13.55M
Operating Income Ratio	10.19%	-905.72%	-29,013.33%	-6,000.77%	-950.49%
Total Other Income/Expenses	15.50M	3.74M	-5.24M	-3.28M	-162.00K
Income Before Tax	54.30M	-197.60M	-87.93M	-42.28M	-13.72M
Income Before Tax Ratio	14.26%	-888.89%	-30,852.98%	-6,504.62%	-961.85%
Income Tax Expense	5.03M	774.00K	-52.00K	2.56M	1.10M
Net Income	49.27M	-198.38M	-87.88M	-44.84M	-14.82M
Net Income Ratio	12.94%	-892.38%	-30,834.74%	-6,898.00%	-1,038.99%
EPS	0.73	-2.98	-1.52	-0.79	-0.26
EPS Diluted	0.70	-2.98	-1.52	-0.79	-0.26
Weighted Avg Shares Out	67.23M	66.51M	57.86M	56.47M	56.47M
Weighted Avg Shares Out (Dil)	69.99M	66.51M	57.86M	56.47M	56.47M

Levi & Korsinsky Notifies Shareholders of Amylyx Pharmaceuticals, Inc.(AMLX) of a Class Action Lawsuit and an Upcoming Deadline

April 8, 2024accesswire.com

NEW YORK, NY / ACCESSWIRE / April 8, 2024 / If you suffered a loss on your Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for...

Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024

April 8, 2024businesswire.com

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the Company will host a virtual webcast with management and Fumihiko Urano, MD, PhD, Principal Investigator of the HELIOS clinical trial and the Samuel E. Schechter...

Levi & Korsinsky Notifies Shareholders of Amylyx Pharmaceuticals, Inc.(AMLX) of a Class Action Lawsuit and an Upcoming Deadline

April 8, 2024accesswire.com

FINAL DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Amylyx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

April 8, 2024accesswire.com

LOS ANGELES, CA / ACCESSWIRE / April 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX) for violations of §§10(b)...

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Amylyx Pharmaceuticals, Inc.(AMLX) Shareholders

April 8, 2024prnewswire.com

NEW YORK , April 8, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Amylyx Pharmaceuticals, Inc. ("Amylyx" or the "Company") (NASDAQ: AMLX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf...

Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights - AMLX

April 8, 2024accesswire.com

AMLX LAWSUIT ALERT: Levi & Korsinsky Notifies Amylyx Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

April 7, 2024accesswire.com

NEW YORK, NY / ACCESSWIRE / April 7, 2024 / If you suffered a loss on your Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for...